Hetty Carraway, MD

Articles by Hetty Carraway, MD

Dr Carraway on Currently Available Treatment Options for AML

ByHetty Carraway, MD

June 6th 2024

Hetty E. Carraway, MD, MBA, discusses current treatment strategies available for patients with acute myeloid leukemia.

Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic

Dr Carraway on the Importance of NGS in Relapsed/Refractory AML

ByHetty Carraway, MD

May 29th 2024

Hetty E. Carraway, MD, MBA, discusses the importance of testing for targetable mutations in patients with relapsed/refractory acute myeloid leukemia.

Durable Outcomes with Manageable Safety Leading to Prolonged Survival with Tagraxofusp for Treatment-Naive Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Updated Results from a European Named Patient Program

ByHetty Carraway, MD

January 29th 2024

Hetty Carraway, MD, presents the updated results, with over two years of follow-up, in treatment-naïve patients with BPDCN to assess tagraxofusp safety and efficacy in the real-world setting.

Final Thoughts on Recent Data Updates in MDS

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

August 17th 2023

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Key Trials in the Treatment of Higher-Risk MDS

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

August 10th 2023

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

August 10th 2023

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

Oral HMAs in Lower-Risk MDS Treatment

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

August 3rd 2023

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

August 3rd 2023

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 28th 2023

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 28th 2023

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

Treatment Approaches for Lower-Risk MDS With RAS Mutations

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 20th 2023

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 20th 2023

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 13th 2023

Panelists review the presented patient profile and shares how they would have approached treatment.

Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 13th 2023

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 10th 2023

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 10th 2023

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

Unmet Needs and Future Perspectives in Treatment of MDS

ByRalph V. Boccia, MD, FACP, LLC, Georgetown University Medical Center,Hetty Carraway, MD

July 6th 2023

Expert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.

Clinical Management of Patients with Lower-risk MDS

ByRalph V. Boccia, MD, FACP, LLC, Georgetown University Medical Center,Hetty Carraway, MD

July 6th 2023

Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.

Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 3rd 2023

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

July 3rd 2023

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Emerging Therapies for Treatment of MDS

ByRalph V. Boccia, MD, FACP, LLC, Georgetown University Medical Center,Hetty Carraway, MD

June 29th 2023

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

Safety and Efficacy of Luspatercept in Frontline Setting in Patients with MDS

ByRalph V. Boccia, MD, FACP, LLC, Georgetown University Medical Center,Hetty Carraway, MD

June 29th 2023

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Risk Stratification of MDS

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Diagnosing Myelodysplastic Syndromes (MDS)

ByRami Komrokji, MD,Andrew Brunner, MD,Hetty Carraway, MD,Yazan Madanat, MD,Amer Zeidan, MBBS, MHS

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Clinical Use of Luspatercept on Patients with Lower-risk MDS

ByRalph V. Boccia, MD, FACP, LLC, Georgetown University Medical Center,Hetty Carraway, MD

June 22nd 2023

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Frontline Treatment Options for Lower-Risk MDS

ByRalph V. Boccia, MD, FACP, LLC, Georgetown University Medical Center,Hetty Carraway, MD

June 22nd 2023

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Importance of Early Diagnosis of MDS for Lower and Higher-risk Patients

ByRalph Boccia, MD, Johns Hopkins Medicine,Hetty Carraway, MD

June 15th 2023

Hetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.

Risk Stratification of Myelodysplastic Syndromes [MDS]

ByRalph Boccia, MD, Johns Hopkins Medicine,Hetty Carraway, MD

June 15th 2023

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

Future Directions in the Management of Acute Myeloid Leukemia

ByJorge E. Cortes, MD,Brian Andrew Jonas, MD, PhD,Margaret T. Kasner, MD,Hetty Carraway, MD

March 21st 2023

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.